- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02732795
Sleep Apnea and Obesity Affects on Morphine Pharmacokinetics
Effects of Obstructive Sleep Apnea Syndrome and Obesity on Morphine Pharmacokinetics in Children
Adenotonsillectomy (AT) is one of the most common pediatric surgeries performed, and is estimated to comprise 530,000 procedures in children under 15 years of age. Historically, the leading cause for these procedures was recurrent infections; however, more recently surgical indications include sleep disordered breathing and obstructive sleep apnea (OSAS). Pre-operative polysomnography (PSG) is recommended for all children with suspected OSAS prior to undergoing AT, although it is unclear whether sleep disordered breathing characteristics predict post-operative outcomes or complications.
Obesity has become an epidemic in the pediatric population. More recently, an increased population of obese children are presenting for AT with upper airway obstruction with or without tonsillar hypertrophy, which is similar to the adult etiology of OSAS. Obesity is a multisystem disease, causing fatty liver and cardiac disease, defects in glucose metabolism, insulin resistance, leptin resistance, and creates a state of chronic inflammation. Markers for inflammation, including tumor necrosis factor (TNF)-α, C-reactive protein (CRP), leptin, interleukin (IL)-6 and IL-10, are abnormal in obese patients and have also been linked to more severe OSAS disease in children even after controlling for BMI.
In pediatrics, medication dosing is based on an actual body-weight calculation, however, recent reports suggest that this dosing method is over-dosing patients with obesity. Therefore, increased respiratory complications after surgery may be related to inappropriate intra-operative opioid dosing.
Specific Aim 1 (SA1): To compare morphine pharmacokinetics in normal children <=12 years of age, non-obese children with severe OSAS, and obese children with severe OSAS. The investigators hypothesize that obesity independently enhances morphine pharmacokinetics.
Specific Aim 2 (SA2): To determine whether biomarkers related to obesity, chronic inflammation, and OSAS predict changes to morphine pharmacokinetics. The investigators hypothesize that inflammatory and obesity-related biomarkers are elevated in overweight children with OSAS, more so in obese children with OSA, compared to lean children with OSAS. In addition, the investigators hypothesizes that leptin independently is linked to altered morphine pharmacokinetics.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Bloomberg Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Child presenting for surgery that will require opioids
- Age between 5 -12 years of age
OSAS group:
- Pre-operative polysomnography study conducted prior to day of surgery
Obese:
- Body weight >95th percentile for age.
Exclusion Criteria:
- Emergency procedures involving AT, including tonsillar bleeding
- Patients allergic to morphine
- Patients with comorbidities altering opioid metabolism (i.e. liver disease)
- Patients with chronic inflammatory, rheumatologic, or other confounding co-morbid diseases (i.e. Crohns disease, ulcerative colitis, sickle cell, Sjogren's, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Morphine dosing
Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS.
Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer.
Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.
|
Each group received morphine and blood drawn to evaluate morphine PK
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Morphine Area Under the Curve (AUC)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in morphine AUC due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Maximum Plasma Morphine Concentration (Cmax)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in morphine Cmax due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Time to Maximum Plasma Morphine Concentration (Tmax)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in morphine Tmax due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Half Life of Plasma Morphine Concentration (T1/2)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in morphine T1/2 due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Plasma Morphine Clearance (Cl)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in morphine Cl due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Plasma Morphine Volume of Distribution (Vd)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in morphine Vd due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Plasma Morphine 3-glucuronide (M3G) Maximum Plasma Concentration (Cmax)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in M3G Cmax due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Time to Maximum Morphine 3-glucuronide (M3G) Concentration (Tmax)
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in M3G Tmax due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Morphine 3-glucuronide (M3G) to Morphine ratio
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in metabolism of morphine due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Morphine 3-glucuronide (M3G) to Morphine 6-glucuronide (M6G) ratio
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine changes in metabolism of morphine due to obesity and OSAS
|
Through study completion, up to 24 hours after study initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarker concentrations
Time Frame: Through study completion, up to 24 hours after study initiation
|
To determine whether inflammatory biomarkers correlate to the severity of sleep apnea.
Biomarkers that will be studied include IL 1,6,10, CRP, TNF-alpha, leptin, and insulin.
|
Through study completion, up to 24 hours after study initiation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Signs and Symptoms, Respiratory
- Sleep Apnea Syndromes
- Obesity
- Apnea
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Morphine
Other Study ID Numbers
- IRB00034512
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Morphine pharmacokinetic evaluation
-
OHSU Knight Cancer InstituteOregon Health and Science University; Janssen, LP; The Leukemia and Lymphoma...TerminatedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterCompletedMetastatic Carcinoma in the Adrenal Cortex | Stage III Adrenal Cortex Carcinoma AJCC v8 | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditionsUnited States, Puerto Rico
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Carcinoma | Bladder Cancer Stage 0 | Bladder Cancer Stage IUnited States
-
IRCCS Eugenio MedeaCompletedIntellectual Disability | Autism Spectrum Disorder | Attention Deficit Hyperactivity DisorderItaly
-
University of California, San FranciscoCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States
-
VA Office of Research and DevelopmentCompleted
-
University Hospital, BordeauxRoche Pharma AGRecruitingMultiple Sclerosis, Primary ProgressiveFrance
-
University of Colorado, DenverCompletedSubarachnoid HemorrhageUnited States